awgldk
/
wikidata
/
Login
Register
TriplyDB
Wikidata
Browser
Triples
Insights
Schema
BETA
Class frequency
Class hierarchy
SPARQL
Graphs
1
Q50119590-084912BF-B144-4E0B-BD7D-B6E322599193
Q50119590-084912BF-B144-4E0B-BD7D-B6E322599193
BestRank
Statement
http://www.wikidata.org/entity/statement/Q50119590-084912BF-B144-4E0B-BD7D-B6E322599193
Impact of ritonavir dose and schedule on CYP3A inhibition and venetoclax clinical pharmacokinetics.
P2860
Q50119590-084912BF-B144-4E0B-BD7D-B6E322599193
BestRank
Statement
http://www.wikidata.org/entity/statement/Q50119590-084912BF-B144-4E0B-BD7D-B6E322599193
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
5d8f8ba29ff3dd0c4ed47173e527bd3e87d3fc67
P2860
Pharmacokinetics of Venetoclax, a Novel BCL-2 Inhibitor, in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Non-Hodgkin Lymphoma.